These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 34767258)

  • 1. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.
    Tarantino P; Carmagnani Pestana R; Corti C; Modi S; Bardia A; Tolaney SM; Cortes J; Soria JC; Curigliano G
    CA Cancer J Clin; 2022 Mar; 72(2):165-182. PubMed ID: 34767258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Drug Conjugates and Tissue-Agnostic Drug Development: An Update.
    Dias E Silva D; Andriatte GM; Pestana RC
    Cancer J; 2022 Nov-Dec 01; 28(6):462-468. PubMed ID: 36383909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
    Parisi C; Mahjoubi L; Gazzah A; Barlesi F
    Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
    Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
    Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates in solid tumors: a look into novel targets.
    Criscitiello C; Morganti S; Curigliano G
    J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?
    Corti C; Antonarelli G; Valenza C; Nicolò E; Rugo H; Cortés J; Harbeck N; Carey LA; Criscitiello C; Curigliano G
    Eur J Cancer; 2022 Aug; 171():25-42. PubMed ID: 35696887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
    Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
    Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan.
    Neupane N; Thapa S; Bhattarai A; Ahuja K; Schlam I; Mittal A; Tolaney SM; Tarantino P
    Curr Oncol Rep; 2023 Dec; 25(12):1467-1482. PubMed ID: 37938529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads.
    Boni V; Sharma MR; Patnaik A
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-17. PubMed ID: 32315240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
    Verma S; Breadner D; Raphael J
    Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
    Nader-Marta G; Molinelli C; Debien V; Martins-Branco D; Aftimos P; de Azambuja E; Awada A
    Ther Adv Med Oncol; 2023; 15():17588359231183679. PubMed ID: 37435563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress.
    Rosner S; Valdivia A; Hoe HJ; Murray JC; Levy B; Felip E; Solomon BJ
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e389968. PubMed ID: 37163707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
    Desai A; Abdayem P; Adjei AA; Planchard D
    Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rise of Antibody-Drug Conjugates: The Present and Future.
    Shastry M; Gupta A; Chandarlapaty S; Young M; Powles T; Hamilton E
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390094. PubMed ID: 37229614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
    Kondrashov A; Sapkota S; Sharma A; Riano I; Kurzrock R; Adashek JJ
    Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
    Shastry M; Jacob S; Rugo HS; Hamilton E
    Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial Cancer.
    Alhalabi O; Altameemi L; Campbell MT; Meric-Bernstam F
    Cancer J; 2022 Nov-Dec 01; 28(6):417-422. PubMed ID: 36383903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
    Bosi C; Bartha Á; Galbardi B; Notini G; Naldini MM; Licata L; Viale G; Mariani M; Pistilli B; Ali HR; André F; Piras M; Callari M; Barreca M; Locatelli A; Viganò L; Criscitiello C; Pusztai L; Curigliano G; Győrffy B; Dugo M; Bianchini G
    Eur J Cancer; 2023 Dec; 195():113379. PubMed ID: 37913680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates for urothelial carcinoma.
    Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
    Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.